tetano
Editor, Senior Moderator
Public Health
. 2021 Aug 16;199:17-19.
doi: 10.1016/j.puhe.2021.08.005. Online ahead of print.
National population prevalence of antibodies to SARS-CoV-2 among pregnant women in Scotland during the second wave of the COVID-19 pandemic: a prospective national serosurvey
A McAuley[SUP] 1 [/SUP], P Gousias[SUP] 2 [/SUP], T Hasan[SUP] 2 [/SUP], L Rashid[SUP] 3 [/SUP], C Richardson[SUP] 4 [/SUP], G Reid[SUP] 2 [/SUP], K Templeton[SUP] 3 [/SUP], J McGuire[SUP] 4 [/SUP], H Wise[SUP] 3 [/SUP], L McVicar[SUP] 3 [/SUP], S Jenks[SUP] 3 [/SUP], R Gunn[SUP] 3 [/SUP], E Dickson[SUP] 2 [/SUP], S J Stock[SUP] 5 [/SUP], A Stockton[SUP] 2 [/SUP], C Waugh[SUP] 2 [/SUP], R Wood[SUP] 6 [/SUP], J McMenamin[SUP] 2 [/SUP], C Robertson[SUP] 7 [/SUP], D J Goldberg[SUP] 8 [/SUP], N E Palmateer[SUP] 9 [/SUP]
Affiliations
Abstract
Objectives: This study aimed to determine SARS-CoV-2 seroprevalence among pregnant women in the Scottish population during the second wave of the COVID-19 pandemic.
Study design: Prospective national serosurvey.
Methods: We tested 13,428 residual samples retrieved from pregnant women participating in the first trimester combined ultrasound and biochemical screening for fetal trisomy across Scotland for SARS-CoV-2 antibodies over a 6-month period from November 2020 to April 2021. Seroprevalence estimates were adjusted for the sensitivity and specificity of the assays and weighted to reference populations.
Results: Seroprevalence rates in the antenatal samples significantly increased from 5.5% (95% confidence interval [CI] 4.7%-6.5%) in the 5-week period up to and including International Organization for Standardization (ISO) Week 51 (w/b Monday 14 December 2020) to 11.3% (95% CI 10.1%-12.6%) in the 5-week period up to and including ISO Week 14 (w/b Monday 5 April 2021). Increasing seroprevalence trends across the second wave were observed among all age groups.
Conclusions: By the end of the second wave of the COVID-19 pandemic, approximately one in 10 women tested around the end of the first trimester of pregnancy had antibodies to SARS-CoV-2, suggesting that the vast majority were still susceptible to COVID-19 as they progressed to the later stages of pregnancy, when risks from infection are elevated for both mother and baby.
Keywords: Antenatal; Antibodies; COVID-19; Coronavirus; Pregnancy; SARS-CoV-2; Serology; Seroprevalence.
. 2021 Aug 16;199:17-19.
doi: 10.1016/j.puhe.2021.08.005. Online ahead of print.
National population prevalence of antibodies to SARS-CoV-2 among pregnant women in Scotland during the second wave of the COVID-19 pandemic: a prospective national serosurvey
A McAuley[SUP] 1 [/SUP], P Gousias[SUP] 2 [/SUP], T Hasan[SUP] 2 [/SUP], L Rashid[SUP] 3 [/SUP], C Richardson[SUP] 4 [/SUP], G Reid[SUP] 2 [/SUP], K Templeton[SUP] 3 [/SUP], J McGuire[SUP] 4 [/SUP], H Wise[SUP] 3 [/SUP], L McVicar[SUP] 3 [/SUP], S Jenks[SUP] 3 [/SUP], R Gunn[SUP] 3 [/SUP], E Dickson[SUP] 2 [/SUP], S J Stock[SUP] 5 [/SUP], A Stockton[SUP] 2 [/SUP], C Waugh[SUP] 2 [/SUP], R Wood[SUP] 6 [/SUP], J McMenamin[SUP] 2 [/SUP], C Robertson[SUP] 7 [/SUP], D J Goldberg[SUP] 8 [/SUP], N E Palmateer[SUP] 9 [/SUP]
Affiliations
- PMID: 34517289
- DOI: 10.1016/j.puhe.2021.08.005
Abstract
Objectives: This study aimed to determine SARS-CoV-2 seroprevalence among pregnant women in the Scottish population during the second wave of the COVID-19 pandemic.
Study design: Prospective national serosurvey.
Methods: We tested 13,428 residual samples retrieved from pregnant women participating in the first trimester combined ultrasound and biochemical screening for fetal trisomy across Scotland for SARS-CoV-2 antibodies over a 6-month period from November 2020 to April 2021. Seroprevalence estimates were adjusted for the sensitivity and specificity of the assays and weighted to reference populations.
Results: Seroprevalence rates in the antenatal samples significantly increased from 5.5% (95% confidence interval [CI] 4.7%-6.5%) in the 5-week period up to and including International Organization for Standardization (ISO) Week 51 (w/b Monday 14 December 2020) to 11.3% (95% CI 10.1%-12.6%) in the 5-week period up to and including ISO Week 14 (w/b Monday 5 April 2021). Increasing seroprevalence trends across the second wave were observed among all age groups.
Conclusions: By the end of the second wave of the COVID-19 pandemic, approximately one in 10 women tested around the end of the first trimester of pregnancy had antibodies to SARS-CoV-2, suggesting that the vast majority were still susceptible to COVID-19 as they progressed to the later stages of pregnancy, when risks from infection are elevated for both mother and baby.
Keywords: Antenatal; Antibodies; COVID-19; Coronavirus; Pregnancy; SARS-CoV-2; Serology; Seroprevalence.